FDA hands approval to Janssens BRCApositive prostate cancer combo tablet Endpoints News

John­son & John­son’s Janssen scored an FDA ap­proval with its li­censed PARP in­hibitor ni­ra­parib in com­bi­na­tion with abi­raterone ac­etate for the treat­ment of BR­CA-pos­i­tive metasta­t­… [+588 chars]Read More